Subgroup analyses of a phase III trial comparing tivozanib hydrochloride versus sorafenib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC) Meeting Abstract


Authors: Hutson, T. E.; Nosov, D.; Eisen, T.; Lipatov, O. N.; Tomczak, P.; Alyasova, A.; Harza, M.; Kogan, M.; Alexseev, B. Y.; Szczylik, C.; Strahs, A. L.; Esteves, B.; Berkenblit, A.; Motzer, R. J.
Abstract Title: Subgroup analyses of a phase III trial comparing tivozanib hydrochloride versus sorafenib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC)
Meeting Title: 2013 Genitourinary Cancers Symposium
Journal Title: Journal of Clinical Oncology
Volume: 31
Issue: 6 Suppl.
Meeting Dates: 2013 Feb 14-16
Meeting Location: Orlando, FL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2013-02-20
Language: English
ACCESSION: WOS:000333679600352
DOI: 10.1200/jco.2013.31.6_suppl.354
PROVIDER: wos
Notes: Meeting Abstract: 354 -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Robert Motzer
    1243 Motzer